DDD in lumbar discs can cause lower back pain, osteoarthritis, abnormal disc bulging (herniated disc) and spinal stenosis (narrowing of the tunnel-like space that holds the spinal cord), any of which can exert pressure on spinal nerves and the spinal cord causing pain and affecting nerve function.
BMAC contains mesenchymal stem cells and CD34+ stem cells. Mesenchymal stem cells have been shown to promote tissue growth including cartilage and CD34+ stem cells can promote tissue vascularization, thus increasing blood supply to new or damaged tissue.
The researchers studied 26 patients who were suffering from discogenic lower back pain. Patients were followed up at 3, 6, and 12 months.
After 12 months, 21 out of 26 patients experienced statistically significant improvements in pain scores and impairment. The most dramatic improvements were seen in patients with higher stem cell counts.
The original publication can be found here: https://onlinelibrary.wiley.com/doi/10.1002/stem.1845/epdf
At Riordan Medical Institute, our doctors perform a procedure for degenerative disc disease that is similar to the one described in the Stem Cell Journal study. However, we augment the BMAC injections with umbilical cord and amniotic tissue products developed by Dr. Riordan. Inclusion of these products add a new dimension to the tissue repair process that was successfully tested in the cited study.
We also employ umbilical cord and amniotic tissue products without BMAC for disc treatments.